|
[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
|
|
[2]JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al.Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J].J Clin Oncol, 2015, 33 (6) :550-558.
|
|
[3]WANG YY, ZHONG JH, SU ZY, et al.Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J].Br J Surg, 2016, 103 (6) :725-734.
|
|
[4]HIRAOKA A, KUMADA T, KUDO M, et al.Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma:Multicenter analysis[J].Dig Dis, 2017, 35 (6) :602-610.
|
|
[5]GUI B, WEINER AA, NOSHER J, et al.Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization[J].Am J Clin Oncol, 2018, 41 (9) :861-866.
|
|
[6]OH IS, SINN DH, KANG TW, et al.Liver function assessment using albumin-bilirubin grade for patients with very earlystage hepatocellular carcinoma treated with radiofrequency ablation[J].Dig Dis Sci, 2017, 62 (11) :3235-3242.
|
|
[7]NA SK, YIM SY, SUH SJ, et al.ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma[J].J Surg Oncol, 2018, 117 (5) :912-921.
|
|
[8]CHAN AW, CHONG CC, MO FK, et al.Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2017, 32 (1) :221-228.
|
|
[9]CHAN AW, KUMADA T, TOYODA H, et al.Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma[J].JGastroenterol Hepatol, 2016, 31 (7) :1300-1306.
|
|
[10]MA XL, ZHOU JY, GAO XH, et al.Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma[J].Clin Chim Acta, 2016, 462:15-22.
|
|
[11]DONG ZR, ZOU J, SUN D, et al.Preoperative albumin-bilirubin score for postoperative solitary hepatocellular carcinoma within the Milan Criteria and Child-Pugh A cirrhosis[J].JCancer, 2017, 8 (18) :3862-3867.
|
|
[12]HO SY, HSU CY, LIU PH, et al.Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma[J].Eur J Surg Oncol, 2019, 45 (5) :776-781.
|
|
[13]CHAN AWH, ZHONG J, BERHANE S, et al.Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection[J].J Hepatol, 2018, 69 (6) :1284-1293.
|
|
[14]AMISAKI M, UCHINAKA E, MORIMOTO M, et al.Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection[J].Hepatobiliary Pancreat Dis Int, 2018, 17 (6) :502-509.
|
|
[15]LI C, ZHANG XY, PENG W, et al.Postoperative albumin-bilirubin grade change predicts the prognosis of patients with hepatitis B-related hepatocellular carcinoma within the Milan Criteria[J].World J Surg, 2018, 42 (6) :1841-1847.
|
|
[16]RAHBARI NN, GARDEN OJ, PADBURY R, et al.Posthepatectomy liver failure:A definition and grading by the International Study Group of Liver Surgery (ISGLS) [J].Surgery, 2011, 149 (5) :713-724.
|
|
[17]ZOU H, WEN Y, YUAN K, et al.Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients[J].Liver Int, 2018, 38 (3) :494-502.
|
|
[18]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
|
|
[19]CHOK K, CHAN SC, FUNG JY, et al.Survival outcomes of right-lobe living donor liver transplantation for patients with high Model for End-stage Liver Disease scores[J].Hepatobiliary Pancreat Dis Int, 2013, 12 (3) :256-262.
|
|
[20]ZHANG W, LIU C, TAN Y, et al.Albumin-bilirubin score for predicting post-transplant complications following adult-toadult living donor liver transplantation[J].Ann Transplant, 2018, 23:639-646.
|
|
[21]KAO WY, SU CW, CHIOU YY, et al.Hepatocellular carcinoma:Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation[J].Radiology, 2017, 285 (2) :670-680.
|
|
[22]OMAGARI K, OHBA K, KADOKAWA Y, et al.Comparison of the grade evaluated by“Liver damage”of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma[J].Hepatol Res, 2006, 34 (4) :266-272.
|
|
[23]HIRAOKA A, KUMADA T, HIROOKA M, et al.A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation:Usefulness of albumin-bilirubin grade[J].Hepatol Res, 2018, 48 (3) :e61-e67.
|
|
[24]CHONG CCN, LEE KF, CHU CM, et al.Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function:Application of ALBI score to patient selection[J].HPB, 2018, 20 (6) :546-554.
|
|
[25]HICKEY R, MOULI S, KULIK L, et al.Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma[J].J Vasc Interv Radiol, 2016, 27 (6) :795-802.
|
|
[26]WAKED I, BERHANE S, TOYODA H, et al.Transarterial chemoembolisation of hepatocellular carcinoma:Impact of liver function and vascular invasion[J].Br J Cancer, 2017, 116 (4) :448-454.
|
|
[27]MOHAMMED MAA, KHALAF MH, LIANG T, et al.Albuminbilirubin score:An accurate predictor of hepatic decompensation in high-risk patients undergoing transarterial chemoembolization for hepatocellular carcinoma[J].J Vasc Interv Radiol, 2018, 29 (11) :1527-1534.
|
|
[28]OGASAWARA S, CHIBA T, OOKA Y, et al.Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma[J].Invest New Drugs, 2015, 33 (6) :1257-1262.
|
|
[29]KUO YH, WANG JH, HUNG CH, et al.Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use[J].J Gastroenterol Hepatol, 2017, 32 (12) :1975-1981.
|
|
[30]KYROCHRISTOS ID, ZIOGAS DE, ROUKOS DH.Regorafenib:Anewly approved drug for advanced hepatocellular carcinoma[J].Future Oncol, 2017, 13 (19) :1665-1668.
|
|
[31]LEE PC, CHEN YT, CHAO Y, et al.Validation of the albuminbilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma[J].Liver Int, 2018, 38 (2) :321-330.
|
|
[32]YUKIMOTO A, HIROOKA M, HIRAOKA A, et al.Using ALBIscore at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma[J].Jpn J Clin Oncol, 2019, 49 (1) :42-47.
|
|
[33]SHAO L, SHI YX, ZHU HX, et al.Clinical effect of stereotactic body radiotherapy combined with Kanglaite injection in treatment of primary liver cancer[J].Chin J Med Offic, 2017, 45 (3) :313-315. (in Chinese) 邵亮, 施艳新, 朱慧心, 等.立体定向放射治疗联合康莱特注射液治疗原发性肝癌临床研究[J].临床军医杂志, 2017, 45 (3) :313-315.
|
|
[34]PAN CC, KAVANAGH BD, DAWSON LA, et al.Radiationassociated liver injury[J].Int J Radiat Oncol Biol Phys, 2010, 76 (3 Suppl) :s94-s100.
|
|
[35]LO CH, LIU MY, LEE MS, et al.Comparison between ChildTurcotte-Pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy[J].Int J Radiat Oncol Biol Phys, 2017, 99 (1) :145-152.
|
|
[36]GKIKA E, BETTINGER D, KRAFFT L, et al.The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy[J].Strahlenther Onkol, 2018, 194 (5) :403-413.
|
|
[37]MURRAY LJ, SYKES J, BRIERLEY J, et al.Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT) [J].Int J Radiat Oncol Biol Phys, 2018, 101 (4) :900-909.
|
|
[38]HO CHM, CHIANG CL, LEE FAS, et al.Comparison of platelet-albumin-bilirubin (PALBI) , albumin-bilirubin (ALBI) , and Child-Pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT) [J].Oncotarget, 2018, 9 (48) :28818-28829.
|
|
[39]Nivolumab approved for liver cancer[J].Cancer Discov, 2017, 7 (11) :OF3.
|
|
[40]HARIMOTO N, YOSHIZUMI T, SAKATA K, et al.Prognostic significance of combined albumin-bilirubin and tumor-node-metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma[J].Hepatol Res, 2017, 47 (12) :1289-1298.
|
|
[41]COUSSENS LM, WERB Z.Inflammation and cancer[J].Nature, 2002, 420 (6917) :860-867.
|
|
[42]LI C, ZHANG XY, PENG W, et al.Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection[J].Medicine (Baltimore) , 2018, 97 (29) :e11599.
|
|
[43]LIU PH, HSU CY, HSIA CY, et al.ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLCstages in the MELD Era[J].J Gastroenterol Hepatol, 2017, 32 (4) :879-886.
|
|
[44]MAI RY, YE JZ, WANG YY, et al.Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (2) :292-297. (in Chinese) 麦荣云, 叶甲舟, 王言焱, 等.ALBI联合APRI对HBV相关肝细胞癌肝切除术后肝衰竭发生的预测价值[J].临床肝胆病杂志, 2018, 34 (2) :292-297.
|
|
[45] FAN J, SHI YH, TIAN YX.Prevention and treatment strategies of postoperative tumor recurrence after liver transplantation for hepatocellular carcinoma[J].Chin J Dig Surg, 2019, 18 (1) :20-23. (in Chinese) 樊嘉, 史颖弘, 田盂鑫.肝癌肝移植术后肿瘤复发的防治策略[J].中华消化外科杂志, 2019, 18 (1) :20-23.
|
|
[46]LIU YS.Role of modified albumin-vilirubin (ALBI) grade for evaluation of liver function and prognoses of patients with hepatocellular carcinoma[D].Fuzhou:Fujian Medical University, 2016. (in Chinese) 刘有顺.改良的ALBI分级在评估肝细胞癌患者肝功能及其预后中的作用[D].福州:福建医科大学, 2016.
|
PDF下载 ( 1933 KB)
本文二维码
下载:
